Nautilus Biotechnology Inc (NAUT) Stock Price, Quote & News

Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 333 2001

Website: www.nautilus.bio

Address:

2701 Eastlake Avenue East, Seattle, United States

birdupyoubird Jan. 28 at 11:48 PM

$NAUT Just do it already. Blast off ASTRONAUT.

0 · Reply

jimbecker Jan. 27 at 5:15 PM

$NAUT Trying to break out of a Double Bottom pattern with a pivot @ $2.29. No volume yet.

0 · Reply

bilocelhi Jan. 23 at 1:10 PM

Moves coming shortly in $NAUT and $HCAT

1 · Reply

MrFibbz Jan. 22 at 6:18 PM

$NAUT What’s everyone’s target here? Weekly looks like it wants to rip but not sure if I want to start a position here

0 · Reply

Eroc Jan. 22 at 3:36 PM

$NAUT we need volume here amigos! Let's go bulls!

0 · Reply

Eroc Jan. 21 at 8:47 PM

$NAUT to add or not to add? Now that is the question! Let's go bulls!

0 · Reply

Eroc Jan. 21 at 3:22 PM

$NAUT c'mon bulls, let's get some volume on this one and get a close above $2.50!! Let's go bulls!

0 · Reply

buysellrepeatreboot Jan. 21 at 3:21 PM

$NAUT

0 · Reply

WOLFSTREET Jan. 19 at 4:24 AM

$NAUT

0 · Reply

LEOJOZS Jan. 16 at 3:58 PM

$NAUT need to step through angular resistance at parallel yellow lines and hold angular off lows at parallel mint green duo to make push up fib series. need to fully flip the .23 fib to start climb and fend off push to recovery lower blue vector gaps and retest of 0 fib

0 · Reply

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

Oct 28, 2025, 11:31 AM EDT - 3 months ago

Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript

Sep 8, 2025, 4:57 PM EDT - 5 months ago

Nautilus Biotechnology, Inc. (NAUT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Nautilus Biotechnology to Participate in Upcoming September Investor Conferences

Aug 1, 2025, 4:45 PM EDT - 6 months ago

Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript

Jul 31, 2025, 8:00 AM EDT - 6 months ago

Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 8:00 AM EDT - 7 months ago

Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025

Apr 29, 2025, 1:01 PM EDT - 9 months ago

Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript

Feb 28, 2025, 6:59 PM EST - 1 year ago

Nautilus: Trading Below An Albeit Lower Net Cash Figure

Feb 28, 2025, 7:25 AM EST - 1 year ago

Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:50 AM EST - 1 year ago

Nautilus Biotechnology layoffs 16% of workforce, plans release of commercial platform in 2026

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

Oct 29, 2024, 1:17 PM EDT - 1 year ago

Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript

Jul 30, 2024, 3:16 PM EDT - 1 year ago

Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024

Apr 30, 2024, 1:19 PM EDT - 1 year ago

Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

Feb 28, 2024, 1:13 PM EST - 2 years ago

Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 8:00 AM EST - 2 years ago

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 22, 2024, 8:00 AM EST - 2 years ago

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference

Feb 7, 2024, 8:00 AM EST - 2 years ago

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Nov 30, 2023, 8:00 AM EST - 2 years ago

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

Nov 1, 2023, 8:05 AM EDT - 2 years ago

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

Oct 31, 2023, 11:22 AM EDT - 2 years ago

Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript

Oct 31, 2023, 8:05 AM EDT - 2 years ago

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023

Aug 4, 2023, 8:00 AM EDT - 2 years ago

Nautilus Biotechnology to Participate in Upcoming August Investor Conferences

Aug 2, 2023, 1:33 PM EDT - 2 years ago

Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Nautilus Biotechnology Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 9:23 AM EDT - 2 years ago

Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023

May 24, 2023, 8:05 AM EDT - 2 years ago

Nautilus Biotechnology to Participate in Upcoming June Investor Conferences

May 2, 2023, 6:30 AM EDT - 2 years ago

Nautilus Biotechnology Reports First Quarter 2023 Financial Results

Apr 18, 2023, 4:05 PM EDT - 3 years ago

Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023

Mar 23, 2023, 8:00 AM EDT - 3 years ago

Nautilus Biotechnology to Participate in B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference

Feb 25, 2023, 3:09 PM EST - 3 years ago

Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript

Feb 23, 2023, 6:05 AM EST - 3 years ago

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Feb 21, 2023, 8:00 AM EST - 3 years ago

Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference

Jan 26, 2023, 8:00 AM EST - 3 years ago

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Jan 26, 2023, 7:45 AM EST - 3 years ago

Nautilus Biotechnology Expands to San Diego

Jan 19, 2023, 8:00 AM EST - 3 years ago

Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)

Dec 27, 2022, 10:53 AM EST - 3 years ago

Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs

Nov 1, 2022, 2:35 PM EDT - 3 years ago

Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript

Nov 1, 2022, 6:05 AM EDT - 3 years ago

Nautilus Biotechnology Reports Third Quarter 2022 Financial Results

Sep 23, 2022, 8:00 AM EDT - 3 years ago

Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit

Sep 1, 2022, 8:00 AM EDT - 3 years ago

Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Aug 30, 2022, 8:00 AM EDT - 3 years ago

Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference

Aug 2, 2022, 12:02 PM EDT - 3 years ago

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q2 2022 Results - Earnings Call Transcript

birdupyoubird Jan. 28 at 11:48 PM

$NAUT Just do it already. Blast off ASTRONAUT.

0 · Reply

jimbecker Jan. 27 at 5:15 PM

$NAUT Trying to break out of a Double Bottom pattern with a pivot @ $2.29. No volume yet.

0 · Reply

bilocelhi Jan. 23 at 1:10 PM

Moves coming shortly in $NAUT and $HCAT

1 · Reply

MrFibbz Jan. 22 at 6:18 PM

$NAUT What’s everyone’s target here? Weekly looks like it wants to rip but not sure if I want to start a position here

0 · Reply

Eroc Jan. 22 at 3:36 PM

$NAUT we need volume here amigos! Let's go bulls!

0 · Reply

Eroc Jan. 21 at 8:47 PM

$NAUT to add or not to add? Now that is the question! Let's go bulls!

0 · Reply

Eroc Jan. 21 at 3:22 PM

$NAUT c'mon bulls, let's get some volume on this one and get a close above $2.50!! Let's go bulls!

0 · Reply

buysellrepeatreboot Jan. 21 at 3:21 PM

$NAUT

0 · Reply

WOLFSTREET Jan. 19 at 4:24 AM

$NAUT

0 · Reply

LEOJOZS Jan. 16 at 3:58 PM

0 · Reply

birdupyoubird Jan. 13 at 7:59 PM

$NAUT when we hear more details about the commercial launch this year, I hope to see this stock between 3 and 4

0 · Reply

tievLeaf Jan. 8 at 9:06 AM

$NAUT why does this trash go up and not $QSI like for real lol

1 · Reply

birdupyoubird Jan. 8 at 8:36 AM

$NAUT what a monster move up that was!

0 · Reply

DistributionD Dec. 27 at 9:32 AM

$NAUT Capital seems to prefer stability in metrics rather than volatile growth spurts. Balance‑sheet flexibility may prove significant. Sustained improvement may validate the long‑term thesis. Investors will likely insist on proof before expanding exposure.

0 · Reply

SuperGreenToday Dec. 17 at 7:12 PM

$NAUT Share Price: $1.87 Contract Selected: Jun 18, 2026 $2.5 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.31 – $0.38 Potential Upside: 72% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply